Complete response and HBsAg clearance of advanced hepatocellular carcinoma associated with hepatitis B by DEB−TACE combined systematic therapy: a case report
The concurrent administration of DEB-TACE, lenvatinib, and tislelizumab demonstrated efficacy in achieving a HBsAg clearance for hepatitis B in a patient presenting with advanced HCC and portal vein tumor thrombosis. These findings suggest that a localized regimen incorporating MKIs and ICIs holds promise as a therapeutic approach for select cases of HBV-HCC, potentially leading to a HBsAg clearance of hepatitis B. Large-scale studies are warranted to validate these findings.
Authors
- Baiguo Xu (ORCID: https://orcid.org/0000-0002-0269-5155)
- Zhongsong Gao
- Cui Yufeng
- Qing Ye (ORCID: https://orcid.org/0000-0002-6756-0630)
- Ning Wang (ORCID: https://orcid.org/0000-0003-1410-329X)
- Hao Cui (ORCID: https://orcid.org/0000-0003-1185-5322)
Institutions
- Tianjin University (CN)
- Tianjin Third Central Hospital (CN)
- Tianjin Infectious Diseases Hospital (CN)
- Cell Technology (China) (HK)
- Tianjin Central Hospital of Gynecology Obstetrics (CN)
- Tianjin Medical University (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-11-20
- DOI
- https://doi.org/10.3389/fimmu.2025.1676514
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00